ACCREDO HEALTH INC
Customers
0
None disclosed
Suppliers
5
4 disclosed
Top supplier share
10%
of EXEL revenue · 3M to 2026-04-03
Top supplier by $
$61.1M
EXEL · 3M to 2026-04-03
Latest period
Apr 3, 2026
10-Q filed 2026-05-05
Suppliers 5
Companies that disclose ACCREDO HEALTH INC as a major customer, as a share of their own revenue. 4 active, 1 lapsed.
| Company | % of their revenue | Est. $ from ACCREDO HEALTH INC | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| EXEL EXELIXIS, INC. |
10% | $61.1M | 3M 2026-04-03 | −1.0pp | Active | 10-Q 2026-05-05 |
Accredo Health, Incorporated 10 % 12 % Accredo Health, Incorporated 12 % 11 % 12 % Accredo Health, Incorporated 11 % 11 % 12 % 10 % Accredo Health, Incorporated 12 % 9 % 12 % 10 % Accredo Health, Incorporated 12 % 12 % Accredo Health, Incorporated 11 % 12 % 10 % 12 % Accredo Health, Incorporated 9 % 12 % 10 % 12 % Accredo Health, Incorporated 12 % 12 % Accredo Health, Incorporated 11 % 12 % 10 % Accredo Health, Incorporated 12 % 11 % 12 % 10 % Accredo Health, Incorporated 12 % 10 % 12 % 9 % Accredo Health, Incorporated 12 % 9 % Accredo Health, Incorporated 12 % 10 % 9 % Accredo Health, Incorporated 11 % 9 % 10 % 8 % Accredo Health, Incorporated 10 % 8 % 9 % 8 % Accredo Health, Incorporated 10 % 9 % 9 % Accredo Health, Incorporated 8 % 10 % 8 % 9 % Accredo Health, Incorporated 8 % 10 % Accredo Health, Incorporated 9 % 9 % 11 % Accredo Health, Incorporated 10 % 8 % 9 % 9 % Accredo Health, Incorporated 20,677 9 % 13,445 9 % Accredo Health, Incorporated 18,688 8 % 19,714 11 % Accredo Health, Incorporated 22,495 10 % 18,286 9 % Accredo Health, Incorporated $ 19,714 11 % $ 13,619 14 % Accredo Health, Incorporated $ 18,286 9 % $ 9,440 12 % Accredo Health, Incorporated 81,028 9 % 50,716 11 % 16,631 9 % Accredo Health, Incorporated 9 % 9 % 11 % 7 % Accredo Health, Incorporated 14 % 7 % 13 % 5 % | ||||||
| JAZZ Jazz Pharmaceuticals plc |
6% | $79.5M | FY 2015-12-31 | −8.0pp | Lapsed Last seen 2015-12-31 |
10-K 2017-02-28 |
Accredo Health Group, Inc. — % 6 % 14 % Accredo Health Group, Inc. — % 11 % — % 12 % Accredo Health Group, Inc. 6 % 14 % 16 % | ||||||
| AVADEL PHARMACEUTICALS PLC AVADEL PHARMACEUTICALS PLC |
Named | — | FY 2024-12-31 | — | Active | 10-K 2025-03-03 |
Accredo Health Group, Inc. (“Accredo”), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 22% of gross accounts receivable. Accredo Health Group, Inc. (“Accredo”), which accounted for 28% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 20% of gross accounts receivable. | ||||||
| HRMY Harmony Biosciences Holdings, Inc. |
Named | — | 3M 2026-03-31 | +2.0pp | Active | 10-Q 2026-05-07 |
Accredo Health Group, Inc. (“Accredo”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. accounted for 36% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 26% of gross product revenue. Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 28% of gross accounts receivable. As of December 31, 2025, three customers accounted for 100% of gross accounts receivable, Accredo Health Group, Inc. (“Accredo”), which accounted for 45% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. Accredo Health Group, Inc. (“Accredo”), which accounted for 41% of gross accounts receivable; As of December 31, 2023, three customers accounted for 100% of gross accounts receivable, Accredo Health Group, Inc. (“Accredo”), which accounted for 39% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 30% of gross accounts receivable. PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 36% of gross accounts receivable; and Accredo Health Group, Inc. (“Accredo”), which accounted for 30% of gross accounts receivable. | ||||||
| VRTX VERTEX PHARMACEUTICALS INC / MA |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-13 |
Accredo Health Group, Inc. 12 % 11 % 11 % < 10 % < 10 % Accredo Health Group, Inc. 11 % 11 % 12 % < 10 % < 10 % Accredo Health Group, Inc. 11 % 12 % 12 % < 10 % < 10 % Accredo Health Group, Inc. 12 % 12 % 15 % < 10 % 10 % | ||||||
Alerts are coming
Get an email when ACCREDO HEALTH INC's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.